Topiramate-13C6
CAT:
804-HY-B0122S
Size:
Inquire
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No

Topiramate-13C6
- UNSPSC Description: Topiramate-13C6 (McN 4853-13C6) is the 13C labeled isotope of Topiramate (HY-B0122). Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase[1][2][3].
- Target Antigen: Calcium Channel; Carbonic Anhydrase; GABA Receptor; iGluR; Isotope-Labeled Compounds; Potassium Channel; Sodium Channel
- Type: Isotope-Labeled Compounds
- Related Pathways: Membrane Transporter/Ion Channel;Metabolic Enzyme/Protease;Neuronal Signaling;Others
- Field of Research: Neurological Disease
- Assay Protocol: https://www.medchemexpress.com/topiramate-13c6.html
- Smiles: NS(OC[C@]1(O[13C]([13CH3])([13CH3])O2)[C@@H]2[C@H](O[13C]([13CH3])([13CH3])O3)[C@H]3CO1)(=O)=O
- Molecular Weight: 345.32
- References & Citations: [1]Lyseng-Williamson KA, et al. Topiramate: a review of its use in the treatment of epilepsy. Drugs. 2007;67(15):2231-56.|[2]Kaminski RM, et al. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology. 2004 Jun;46(8):1097-104.|[3]Nakamura J, et al. Target pharmacology of topiramate, a new antiepileptic drug. Nihon Yakurigaku Zasshi. 2000 Jan;115(1):53-7.
- Shipping Conditions: Room temperature
- Clinical Information: No Development Reported